ZyVersa Therapeutics Analyst Ratings
ZyVersa Therapeutics Analyst Ratings
While ratings are subjective and will change, the latest ZyVersa Therapeutics (ZVSA) rating was a initiated with a price target of $0.00 to $2.50. The current price ZyVersa Therapeutics (ZVSA) is trading at is $0.12, which is within the analyst's predicted range.| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 09/08/2023 | 1934.17% | HC Wainwright & Co. | → $2.5 | Initiates Coverage On | → Buy |
| 日期 | 上行/下行 | 分析公司 | 目標價格變動 | 評級變動 | 之前/當前的評級 |
|---|---|---|---|---|---|
| 09/08/2023 | 1934.17% | HC Wainwright & Co. | → 2.5 美元 | 啓動覆蓋範圍開啓 | → 購買 |
What is the target price for ZyVersa Therapeutics (ZVSA)?
ZyVersa Therapeutics（ZVSA）的目標價格是多少？
The latest price target for ZyVersa Therapeutics (NASDAQ: ZVSA) was reported by HC Wainwright & Co. on September 8, 2023. The analyst firm set a price target for $2.50 expecting ZVSA to rise to within 12 months (a possible 1934.17% upside). 1 analyst firms have reported ratings in the last year.
HC Wainwright & Co. 於2023年9月8日公佈了ZyVersa Therapeutics（納斯達克股票代碼：ZVSA）的最新目標股價。該分析公司將目標股價定爲2.50美元，預計ZVSA將在12個月內上漲至1934.17％（可能上漲1934.17％）。去年有1家分析公司公佈了評級。
What is the most recent analyst rating for ZyVersa Therapeutics (ZVSA)?
ZyVersa Therapeutics（ZVSA）的最新分析師評級是多少？
The latest analyst rating for ZyVersa Therapeutics (NASDAQ: ZVSA) was provided by HC Wainwright & Co., and ZyVersa Therapeutics initiated their buy rating.
ZyVersa Therapeutics（納斯達克股票代碼：ZVSA）的最新分析師評級由HC Wainwright & Co. 提供，ZyVersa Therapeutics啓動了買入評級。
When is the next analyst rating going to be posted or updated for ZyVersa Therapeutics (ZVSA)?
ZyVersa Therapeutics（ZVSA）的下一份分析師評級何時發佈或更新？
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of ZyVersa Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for ZyVersa Therapeutics was filed on September 8, 2023 so you should expect the next rating to be made available sometime around September 8, 2024.
分析師在進行了廣泛的研究後得出了股票評級，包括閱讀公開財務報表、與ZyVersa Therapeutics的高管和客戶交談以及聽取業績電話會議。大多數分析師每三個月進行一次評級，因此每家公司每年應獲得4個評級。ZyVersa Therapeutics的最後一次評級是在2023年9月8日提交的，因此你應該預計下一個評級將在2024年9月8日左右公佈。
Is the Analyst Rating ZyVersa Therapeutics (ZVSA) correct?
分析師對ZyVersa Therapeutics（ZVSA）的評級是否正確？
While ratings are subjective and will change, the latest ZyVersa Therapeutics (ZVSA) rating was a initiated with a price target of $0.00 to $2.50. The current price ZyVersa Therapeutics (ZVSA) is trading at is $0.12, which is within the analyst's predicted range.
雖然評級是主觀的，並且會發生變化，但最新的ZyVersa Therapeutics（ZVSA）評級最初的目標股價爲0.00美元至2.50美元。ZyVersa Therapeutics（ZVSA）目前的交易價格爲0.12美元，在分析師的預測區間內。
